UPB - Upstream Bio, Inc.
NEXT EARNINGS:
Mar 11, 2026
(in 14 days)
EPS Est: $-0.73
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$49.00
DETAILS
HIGH:
$51.00
LOW:
$47.00
MEDIAN:
$49.00
CONSENSUS:
$49.00
UPSIDE:
518.69%
Market Cap:
427.99M
Volume:
1,538,501
Avg Volume:
1,098,800
52 Week Range:
5.14-33.68
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.93
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
52
IPO Date:
2024-10-11
EPS (TTM):
-1.49
P/E Ratio:
-13.44
Revenue (TTM):
2.37M
Total Assets:
481.72M
Total Debt:
1.83M
Cash & Equiv:
325.89M
Rev Growth (5Y):
39.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-16.5%
Debt/Equity:
0.00
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.63 | $-0.78 | +19.2% | $683000 | $521570 | +31.0% |
| 2025-08-06 | $-0.74 | $-0.61 | -21.3% | $937000 | $317000 | +195.6% |
| 2025-05-06 | $-0.51 | $-0.49 | -4.1% | $566000 | $317000 | +78.5% |
| 2025-03-13 | $-1.59 | $-0.56 | -183.9% | $613000 | $326250 | +87.9% |
| 2024-11-07 | $-6.96 | $-0.54 | -1200.3% | $607000 | $397250 | +52.8% |
| 2023-12-31 | $-0.14 | — | — | $2.4M | — | — |
| 2023-09-30 | $-0.09 | — | — | $621000 | — | — |
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 2.37M | 2.38M | 1.21M |
| Net Income | (62.81M) | (20.54M) | (23.87M) |
| EPS | -1.49 | -1.05 | -0.66 |
| Total Assets | 481.72M | 117.20M | 18.48M |
| Total Debt | 1.83M | 45,000 | 94,000 |
| Cash & Equivalents | 325.89M | 25.83M | 17.05M |
| Operating Cash Flow | (59.17M) | (37.93M) | (19.02M) |
| Free Cash Flow | (59.68M) | (38.07M) | (19.10M) |
| FCF per Share | -1.16 | -1.05 | -0.53 |
| Book Value | 469.85M | (123.13M) | (106.16M) |
| Cash & ST Investments | 470.45M | 109.81M | 17.05M |
| ROC Equity | -0.13 | N/A | N/A |